Burn Rate and Runway Modeling for Pre-Revenue Biotech Companies

Pre-revenue biotech companies operate under a financial reality that few other businesses share. Development cycles can span five to fifteen years with zero product revenue, meaning the company's entire trajectory depends on how well it manages cash between funding rounds.

A burn rate model is the financial compass of a clinical-stage biotech, and when it's built poorly, the consequences compound quickly: cash shortfalls at critical junctures, stalled research programs, and fundraising conversations that happen from a position of weakness rather than strength.

Getting this right requires more than a simple monthly expense projection. It requires a modeling framework that reflects how biotech companies actually spend money, where the risks concentrate, and what investors expect to see when they evaluate a company's financial planning discipline.

Why Biotech Burn Models Require a Different Approach

Standard startup burn rate math assumes relatively predictable monthly expenses: salaries, rent, software, marketing. Biotech spending patterns look fundamentally different, for three reasons.

First, spending is milestone-driven. Contract research organization (CRO) payments, which represent a significant share of total cash outflows, are structured around operational milestones like site initiation, patient enrollment targets, and database lock. These payments are lumpy and irregular, and they don't align neatly with calendar quarters.

Second, regulatory uncertainty introduces timeline risk that is difficult to parallel in other industries. An FDA request for additional preclinical data can push a trial start by a year or more, adding carrying costs while simultaneously delaying the milestones that would trigger the next phase of development.

Third, the cost structure scales dramatically across development phases. Early-stage programs cost a fraction of late-stage trials, and the jump between phases can be an order of magnitude or more, depending on therapeutic area, trial design, and patient population. A burn model that treats these costs as linear will produce projections that are unreliable precisely when accuracy matters most.

Key Cost Categories to Model

A credible biotech burn model captures several distinct expense categories, each with its own spending dynamics.

 

Clinical Trial Expenditures

Clinical trial costs represent the largest and most variable line item for most pre-revenue biotechs. CRO contracts are typically structured around milestone payments rather than fixed monthly fees, which means cash outflows cluster around specific operational events: site initiation visits, enrollment thresholds, database lock, and final report delivery.

Within an active trial, patient enrollment drives the majority of variable costs. Sites receive per-patient payments for screening, enrollment, and follow-up visits, and the enrollment curve itself is rarely linear. Recruitment tends to start slowly, ramp through mid-study, and taper off as the trial approaches its target. Mapping this curve into the burn model, rather than assuming even monthly spend, produces materially different cash flow projections.

 

R&D Infrastructure

Laboratory facilities, specialized equipment, and scientific personnel represent the baseline burn rate that continues whether or not a clinical trial is actively running. These costs are relatively stable on a monthly basis, but they can include large, discrete transactions when major equipment purchases or facility buildouts occur. The model should account for both the steady-state run rate and any planned capital investments.

 

Regulatory and Compliance

FDA interactions, regulatory consultants, and submission preparation create costs that tend to cluster around filing periods. These expenses are often modest relative to clinical trial spend, but they can spike meaningfully during periods of active regulatory engagement, particularly for companies pursuing accelerated or complex regulatory pathways.

 

Manufacturing and Drug Supply

As programs advance from early to later phases, drug supply requirements scale significantly. Manufacturing partnerships often carry minimum batch commitments, long lead times, and upfront deposits that can create unexpected cash demands if not planned for well in advance.

For companies approaching pivotal trials, R&D cost accounting and manufacturing cost tracking become increasingly important components of the overall financial model.

Building in Risk and Contingency

The difference between a credible burn model and an optimistic spreadsheet is scenario planning. Pre-revenue biotechs operate in an environment where unexpected developments can alter cash requirements dramatically, and the model needs to reflect that.

 

Regulatory Delays

FDA feedback cycles can extend trial timelines by multiple quarters. Each delay adds carrying costs for personnel, facilities, and ongoing site maintenance fees while pushing back the milestones that would demonstrate progress to investors. The model should include scenarios where key regulatory milestones slip, capturing both the extended timeline and any incremental expenses that result.

 

Protocol Amendments

Protocol changes during active trials are common, and they carry real financial consequences. Adding new endpoints, expanding patient populations, or modifying dosing regimens typically triggers contract amendments with CROs that can increase study budgets meaningfully.

Effective models assume at least one significant protocol amendment per study and build contingency reserves accordingly.

 

Enrollment Shortfalls

Patient recruitment frequently runs behind initial projections due to site activation delays, competitive trials recruiting from the same patient population, and higher-than-expected screen failure rates. Conservative modeling should factor in enrollment timelines that run below initial targets, which extends the period of active trial spend and pushes out key milestones.

A three-scenario framework gives leadership and investors the range they need to plan appropriately. A conservative case should assume longer timelines and higher costs. A baseline case should reflect the most likely set of assumptions. An optimistic case should model accelerated timelines with cost efficiencies. Together, these scenarios inform fundraising timing and strategic decision-making far more effectively than a single-point projection.

Presenting the Model to Investors and Boards

A well-built burn model loses much of its value if it's not communicated effectively. Investors in biotech expect milestone-based runway presentations, and they are accustomed to evaluating cash flow projections that reflect the inherent uncertainty of drug development.

An effective board-level presentation should include decision trees that show how different trial outcomes affect future cash requirements. Positive Phase II results, for example, might accelerate Phase III preparation and increase near-term burn while improving long-term value creation prospects. The board needs to see those dynamics mapped out rather than summarized in a single burn figure.

Sensitivity analyses are equally important. Showing how changes in enrollment rates, regulatory timeline assumptions, or CRO cost escalations affect runway gives investors a clear view of the variables that matter most. This level of transparency builds confidence by demonstrating financial discipline and operational awareness, both of which factor heavily into due diligence conversations and future fundraising outcomes.

For companies managing tight liquidity, pairing the long-range burn model with a shorter-term 13-week cash flow forecast provides the operational detail needed to manage week-to-week cash positioning while maintaining strategic visibility over the full development horizon.

Build the Financial Infrastructure Your Biotech Company Needs

Creating accurate burn rate and runway models for a pre-revenue biotech requires specialized understanding of clinical development economics, regulatory processes, and pharmaceutical finance. The complexity of milestone-driven expenses, variable trial costs, and regulatory uncertainties goes well beyond standard startup financial planning.

G-Squared Partners brings deep experience in biotech and life sciences financial modeling. Our team understands the unique dynamics of clinical-stage companies and helps leadership teams build robust models that account for the full range of biotech-specific risks and opportunities.

From preclinical planning through late-stage development, we provide the financial infrastructure and strategic guidance that biotech executives need to make well-informed decisions.

To learn more about how G-Squared Partners can support your company's financial planning, schedule a consultation today.